Literature DB >> 20072072

Development of positron emission tomography imaging by 64Cu-labeled Fab for detecting ERC/mesothelin in a mesothelioma mouse model.

Chisato Yoshida1, Chizuru Sogawa, Atsushi B Tsuji, Hitomi Sudo, Aya Sugyo, Tomoya Uehara, Okio Hino, Yukie Yoshii, Yasuhisa Fujibayashi, Toshimitsu Fukumura, Mitsuru Koizumi, Yasushi Arano, Tsuneo Saga.   

Abstract

BACKGROUND: Malignant mesothelioma is a highly aggressive form of cancer. Curative surgery is the only effective therapy for mesothelioma, and therefore early diagnosis is important. However, early diagnosis is difficult using current diagnostic imaging techniques, and a new imaging method for early diagnosis is urgently required. We evaluated the affinity of radiolabeled monoclonal antibodies to the C-terminal fragment of ERC/mesothelin for this purpose.
METHODS: In-labeled or I-labeled IgG against C-terminal fragment of ERC and its Fab fragment were evaluated in vitro by cell binding, competitive inhibition, and cellular internalization assays, and in vivo by biodistribution in mice bearing ERC-expressing tumors. Next, the Fab fragment was labeled with the positron emitter Cu and evaluated by positron emission tomography (PET).
RESULTS: Radiolabeled IgG and Fab showed specific binding to ERC-expressing mesothelioma cells with high affinity. Both radiolabeled IgG and Fab internalized into cells after binding to ERC on the cell surface. In-labeled IgG accumulated in ERC-expressing tumors and resulted in a moderate tumor-to-blood ratio at 4 days after injection. Furthermore, PET using Cu-labeled Fab visualized the tumor at 6 h after injection.
CONCLUSION: Cu-labeled Fab can be useful for ERC-specific PET imaging, and can thus facilitate improved diagnosis of patients with early-stage mesothelioma.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20072072     DOI: 10.1097/MNM.0b013e328336733d

Source DB:  PubMed          Journal:  Nucl Med Commun        ISSN: 0143-3636            Impact factor:   1.690


  6 in total

1.  Feasibility of large-scale screening using N-ERC/mesothelin levels in the blood for the early diagnosis of malignant mesothelioma.

Authors:  Kohta Imashimizu; Kazu Shiomi; Masahiro Maeda; Naoko Aoki; Kiyoko Igarashi; Fumio Suzuki; Mitsuru Koizumi; Kenji Suzuki; Okio Hino
Journal:  Exp Ther Med       Date:  2011-03-08       Impact factor: 2.447

2.  A novel PET imaging using ⁶⁴Cu-labeled monoclonal antibody against mesothelin commonly expressed on cancer cells.

Authors:  Kazuko Kobayashi; Takanori Sasaki; Fumiaki Takenaka; Hiromasa Yakushiji; Yoshihiro Fujii; Yoshiro Kishi; Shoichi Kita; Lianhua Shen; Hiromi Kumon; Eiji Matsuura
Journal:  J Immunol Res       Date:  2015-03-25       Impact factor: 4.818

Review 3.  Amatuximab and novel agents targeting mesothelin for solid tumors.

Authors:  Paolo Baldo; Sara Cecco
Journal:  Onco Targets Ther       Date:  2017-11-08       Impact factor: 4.147

Review 4.  In commemoration of the 2018 Mataro Nagayo Prize: A road to early diagnosis and monitoring of asbestos-related mesothelioma.

Authors:  Okio Hino; Masaaki Abe; Bo Han; Yan Yan
Journal:  Cancer Sci       Date:  2019-04-08       Impact factor: 6.716

5.  Imaging the distribution of an antibody-drug conjugate constituent targeting mesothelin with ⁸⁹Zr and IRDye 800CW in mice bearing human pancreatic tumor xenografts.

Authors:  Eva J ter Weele; Anton G T Terwisscha van Scheltinga; Jos G W Kosterink; Linda Pot; Silke R Vedelaar; Laetitia E Lamberts; Simon P Williams; Marjolijn N Lub-de Hooge; Elisabeth G E de Vries
Journal:  Oncotarget       Date:  2015-12-08

Review 6.  Antibody Fragment and Affibody ImmunoPET Imaging Agents: Radiolabelling Strategies and Applications.

Authors:  Ruisi Fu; Laurence Carroll; Gokhan Yahioglu; Eric O Aboagye; Philip W Miller
Journal:  ChemMedChem       Date:  2018-11-15       Impact factor: 3.466

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.